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In the 1980s, statins were introduced in clinical practice as lipid-
loweringmedication. Since then, several additional, pleiotropic,
effects of statins have been described, including angiogenic,
antiarrhythmic, antibacterial, anti-inflammatory, antimitotic,
antioxidative, antithrombotic, CRP-lowering, immunomodula-
tory and vascular protective (stabilisation of the atheroma
plaque) activity, inhibition of smooth muscle cell proliferation
and migration, inhibition of cardiac hypertrophy/remodelling,
inhibition of matrix metalloproteinase and cyclooxygenase-2,
inhibition of telomere shortening, and improvement of micro-
vascular function (amelioration of endothelial function) and of
autonomic nervous system function. These pleiotropic effects
rest on the statin-induced inhibition of farnesyl pyrophosphate
(FPP) and geranyl pyrophosphate (GPP) prenylation, resulting
in inhibition of prenylation of the small GTPases Ras, and Rho
and Rac, respectively. These signalling pathways regulate cell
proliferation, hypertrophy, activation of inflammatory cyto-
kines, mRNA stability, gene transcription, and reactive oxygen
species (ROS) generation [1, 2].
With these pleiotropic effects, the now envisaged treatment
targets of statins cover a wide range of conditions and dis-
eases, including stem cell modulation [3], rheumatological
disorders [4], wound healing [5], autoimmune diseases and
cancer [6], premedication prior to percutaneous coronary in-
tervention [7], prevention of stent restenosis [8], adjunctive
therapy in acute coronary syndrome [9], improvement of
saphenous graft patency [10] and prevention of sepsis [11]
and preeclampsia [12].
Statins have been reported to be beneficial in heart failure of
ischaemic and non-ischaemic aetiology [13]. Whereas the ben-
eficial action of statins in heart failure with ischaemic aetiology
could, at least partly, be attributed to the cholesterol-lowering
effect, such an explanation is not tenable in heart failure patients
with normal cholesterol levels or in heart failure of non-
ischaemic nature: this underscores the relevance of the pleio-
tropic action of statins in the setting of heart failure. Experi-
mental studies have shown that statins beneficially influence
hypertrophy, cell death and electrical and contractile function of
cardiomyocytes, and differentiation, proliferation, migration
and extracellular matrix synthesis of cardiac fibroblasts, thus
facilitating improvement of adverse remodelling in heart failure
of ischaemic and non-ischaemic aetiology (reviewed in detail
by Porter and Turner [2]). Hence, the pleiotropic potency of
statins in heart failure is remarkable, and may constitute a
valuable addition to the current pharmacological heart failure
medication consisting of beta blockers, ACE inhibitors, angio-
tensin receptor blockers, aldosterone receptor blockers and
diuretics [1, 2].
There are also less optimistic considerations. Statins might
have harmful effects because of possible detrimental influ-
ences on the inflammation status as a consequence of choles-
terol lowering (cholesterol plays a role in controlling inflam-
mation [14, 15]), and by causing myopathy, due to the statin-
based inhibition of ubiquinone synthesis impairing mitochon-
drial energy production [16] and due to statin-induced de-
creases of selenoprotein levels [17]. Moreover, in contrast to
studies reporting positive effects on survival, clinical status
and cardiac function in heart failure (reviewed in Bonsu et al
[18]., references 6–14 and 24–26), two large RCTs, the CO-
RONA [19] and the GISSI-HF [20] trials, have not yielded
significant improvements of the primary endpoints in patients
treated with rosuvastatin compared with placebo.
It has been suggested [21] that the reason for these seem-
ingly inconsistent or contradictory results may be the fact that
the CORONA and GISSI-HF studies addressed a hydrophilic
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statin (rosuvastatin). In contrast to lipophilic statins such as
atorvastatin, hydrophilic statins as rosuvastatin mainly act in
the liver, while lipophilic statins also reach extra-hepatic tis-
sue, including the myocardium, and could thus exert their
pleiotropic actions there.
Seen in the light of the potential role of statins in heart
failure, notably because of their wide range of pleiotropic
action, further studies are needed, addressing the mechanisms
of action at the molecular and cellular level, the structural and
functional effects on the heart and other target organs or
systems, such as the autonomic nervous system, and looking
at clinical outcome. In the current issue of the Netherlands
Heart Journal, Correale and colleagues describe the results of
a prospective analysis of data from a non-randomised obser-
vational registry, comparing heart failure outpatients with
systolic dysfunction treated with atorvastatin or without
statins [22]. Statin administration depended on clinician judg-
ment: 114 patients, of whom 61% (70 patients) had ischaemic
heart disease, received atorvastatin and 81 patients, of whom
33 % (27 patients) had ischaemic heart disease, had no statin
prescribed. Atorvastatin use was associated with a lower
incidence of cardiac death, and this association remained
statistically significant after correction for age, gender, ejec-
tion fraction, use of ACE inhibitors, and beta-blocker therapy.
Tissue Doppler imaging (TDI) revealed significantly better
parameters of ventricular function in the atorvastatin patients.
Significant differences of the same nature were found between
the ischaemic heart disease subgroups with and without
atorvastatin.
Correale and colleagues stress the importance of the TDI
data that they present: up to now, data relating to cardiac
functioning are scarce in studies regarding the effects of statins
in heart failure. In the Limitations section, they emphasise the
fact that randomised controlled trials are needed to confirm
their results. Because their observations very likely reflect the
pleiotropic effects of the (lipophilic) statin studied, compari-
son of a lipophilic and a hydrophilic statin [1] would be a
logical choice for such a future trial.
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